Craig-Hallum initiated coverage of Myriad Genetics (MYGN) with a Buy rating and $29 price target
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.